Full Press Release Details
STERIS Announces Leadership Succession Plan
DUBLIN, IRELAND - (February 3, 2021) - STERIS plc (NYSE: STE) ( STERIS or the Company ) today announced that Walt Rosebrough, President
and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company s Annual General Meeting. Mr. Rosebrough will remain as CEO Emeritus and Senior Advisor to STERIS s leadership and Board for the
STERIS s Board of Directors has unanimously appointed Dan Carestio, currently Chief Operating Officer (COO), to the Board of
Directors as of January 29, 2021 and Mr. Carestio will succeed Mr. Rosebrough as President and CEO, effective July 29, 2021. The board intends to include Mr. Carestio on the slate of Directors for election at the upcoming
Annual General Meeting, and Mr. Rosebrough has advised the Board that he does not intend to stand for re-election.
I believe that STERIS is stronger and better positioned than ever and has a very talented overall leadership team in place to continue to drive
forward, said Walt Rosebrough, President and CEO. Dan has been with STERIS over twenty years with progressively increasing responsibilities in marketing, sales, and general management. He drove our improvements in Life Sciences and
Applied Sterilization Technologies (AST) segments the past decade. He led the successful integration of the Synergy Health AST business, took on the additional leadership of our Healthcare IPT business when that leader retired, and finally became
responsible for all our operations as COO in 2018. The success of all three of our business segments since he became COO is a testament to Dan and the STERIS leadership team. I am extremely confident that Dan is the right person to lead STERIS into
This announcement follows a well-planned and thoughtful succession process, which prioritizes developing leaders from within the
Company, said Dr. Mohsen Sohi, Chairman of the Board. Dan has a long history of demonstrating his ability to lead and drive results, and the Board has full confidence in him as the next CEO for STERIS. We are fortunate to have had
Walt s leadership for well over a decade, through some of the most challenging times in STERIS s history. During Walt s tenure, we have grown revenue three-fold, completed close to fifty acquisitions, added more than 8,000 people to
our workforce and grown shareholder value nearly 10 times, adding over $14 billion of market capitalization. We are forever grateful for his contributions and look forward to continuing to have access to his counsel and expertise as an advisor
to the Board and senior management for the next two years.
STERIS s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service
solutions around the globe. For more information, visit www.steris.com.
Julie Winter, Vice President, Investor Relations and Corporate Communications
Stephen Norton, Senior Director, Corporate Communications
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements speak only as to the
date the statement is made and may be identified by the use of forward-looking terms such as may, will, expects, believes, anticipates, plans, estimates,
projects, targets, forecasts, outlook, impact, potential, confidence, improve, optimistic, deliver, orders,
backlog, comfortable, trend , and seeks, or the negative of such terms or other variations on such terms or comparable terminology. These forward-looking statements are based on current expectations,
estimates or forecasts about our businesses, the industries in which we operate and current beliefs and assumptions of management and are subject to uncertainty and changes in circumstances. Investors should understand that these statements are not
guarantees of performance or results. Many important factors could affect actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. No assurances can be provided as to any result or
the timing of any outcome regarding matters described in STERIS s or Cantel s securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost
reductions, business strategies, earnings or revenue trends or future financial results. Unless legally required, we do not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or
implied, will not be realized. These risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:
Investors are cautioned not to place undue reliance on any forward-looking statements, which speak only as
of the date they are made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law. This cautionary statement is
applicable to all forward-looking statements contained herein.